Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 23fludarabine 14Rituximab 14Specimen Handling 8Magnetic Resonance Spectroscopy 7Doxorubicin 7pirtobrutinib 6Vincristine 6Prednisone 6zanubrutinib 4polatuzumab vedotin 4obinutuzumab 4Nivolumab 4Etoposide 4Dexamethasone 4Biopsy 4tazemetostat 3tafasitamab 3pembrolizumab 3ibrutinib 3glofitamab 3fludarabine phosphate 3acalabrutinib 3Immunotherapy, Adoptive 3Bendamustine Hydrochloride 3venetoclax 2pomalidomide 2etoposide phosphate 2cemiplimab 2Prednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × MLN 8237 × 90 days × Clear all
NCT01695941 2026-04-13

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡